Diagnosis and treatment of pre-insulin dependent diabetes.
The development of genetic and serological markers of autoimmune Type I diabetes has allowed us to begin to identify subjects at risk for the development of Type I diabetes. Assessment of these variables can assign risk to subjects and permit the implementation of immune intervention trials in an attempt to alter the course of pre-diabetes. This review discusses relevant aspects of the genetics and diagnosis of pre-diabetes, and both current and future clinical trials that are attempting to prevent the full expression of clinical diabetes in these individuals.
Gottlieb
P A
PA
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver 80262, USA. Peter.Gottlieb@UCHSC.edu
Eisenbarth
G S
GS
D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000517:prevention & control / Q000628:therapy; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D005544:Forecasting; D015870:Gene Expression; D005819:Genetic Markers; D006801:Humans; D007167:Immunotherapy; D011236:Prediabetic State / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D012307:Risk Factors
D001323:Autoantibodies; D015415:Biomarkers; D005819:Genetic Markers